[SCHEDULE 13G] Aptevo Therapeutics Inc SEC Filing

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. (APVO) – Schedule 13G filing dated 25 June 2025

The filing discloses the beneficial ownership position of three reporting persons – Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC – in the common stock of Aptevo Therapeutics.

• Initial position (18 Jun 2025): Under the Securities Purchase Agreement ("SPA") the group could have been deemed to own 82,000 shares, or 9.8 % of the then-outstanding 759,156 shares, with potential future ownership of up to 507,500 shares if two warrants (total 425,500 shares) were exercised and blocker provisions were waived.
• Current position (close of business 25 Jun 2025): The reporting persons now report 0 shares beneficially owned, equating to 0.00 % of the class. The share-count denominator used is 2,864,156 shares (759,156 existing + 2,105,000 newly issued at SPA closing).
• Warrant conditions: Both Intracoastal Warrant 1 (410,000 shares) and Warrant 2 (15,500 shares) remain unexercisable until shareholder approval and are each subject to a 9.99 % ownership blocker.

Key takeaways for investors

• The investors that were previously positioned to own almost 10 % of Aptevo now disclose no beneficial ownership, removing a potential large holder from the register.
• Potential dilution from 425,500 warrant shares remains possible, but only after shareholder approval and subject to the 9.99 % cap.
• No financial performance metrics are included; the filing is limited to ownership disclosure.

Positive

• None.

Negative

• Loss of prospective 9.8 % insider stake – the reporting group now holds 0 %, signalling reduced strategic or financial support.
• Ongoing dilution overhang – warrants for 425,500 shares remain outstanding and could dilute shareholders upon exercise.

Insights

Financial Analyst

TL;DR – 10% prospective holder now reports 0%; reduces insider support, raises dilution overhang.

The Kopin/Asher/Intracoastal group originally negotiated to receive 82 k shares (9.8 %) plus warrants for another 425.5 k shares. Following the 2.105 m-share issuance at SPA closing, they now report zero beneficial ownership, placing them below the 5 % reporting threshold. The exit removes a sizable prospective insider but also reduces concentration risk. However, warrants remain outstanding and, if later approved and unblocked, could add up to 14.9 % incremental dilution versus the current share count. Overall, the disclosure is modestly negative because expected strategic capital support appears to have vanished, while dilution risk persists.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aptevo Therapeutics Inc.

(Name of Issuer)

Common stock, par value $0.001 per share

(Title of Class of Securities)

03835L405

(CUSIP Number)

06/18/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03835L405

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 03835L405

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 03835L405

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aptevo Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 2401 4th Avenue, Suite 1050, Seattle, Washington 98121
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common stock, par value $0.001 per share
(e)	CUSIP No.: 03835L405
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on June 18, 2025 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 20, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 82,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock represent beneficial ownership of approximately 9.8% of the Common Stock, based on (1) 759,156 shares of Common Stock outstanding as of June 18, 2025, as reported by the Issuer, plus (2) 82,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 410,000 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1") because Intracoastal Warrant 1 is not exercisable until the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 (and Intracoastal Warrant 1 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock) and (II) 15,500 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 is not exercisable until the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 (and Intracoastal Warrant 2 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock). Without such blocker provisions (and assuming Intracoastal Warrant 1 and Intracoastal Warrant 2 were currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 507,500 shares of Common Stock. (ii) As of the close of business on June 25, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of no shares of Common Stock, and all such shares of Common Stock represent beneficial ownership of approximately 0.00% of the Common Stock, based on (1) 759,156 shares of Common Stock outstanding as of June 18, 2025, as reported by the Issuer, plus (2) 2,105,000 shares of Common Stock issued at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 410,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 is not exercisable until the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 (and Intracoastal Warrant 1 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock) and (II) 15,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 is not exercisable until the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 (and Intracoastal Warrant 2 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock). Without such blocker provisions (and assuming Intracoastal Warrant 1 and Intracoastal Warrant 2 were currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 425,500 shares of Common Stock.
(b)	Percent of class: 0.00%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	06/25/2025

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	06/25/2025

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	06/25/2025

Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

Why did Kopin, Asher & Intracoastal file a Schedule 13G on Aptevo Therapeutics (APVO)?

To disclose their beneficial ownership status following the 18 Jun 2025 Securities Purchase Agreement with Aptevo.

How many APVO shares do the reporting persons currently own?

As of 25 Jun 2025 they report 0 shares, or 0.00 % of Aptevo’s outstanding common stock.

What was the prior ownership percentage before the latest disclosure?

Immediately after signing the SPA, they could have been deemed to own 82,000 shares, or approximately 9.8 %.

How many shares could still be issued to the group via warrants?

Two warrants could deliver 425,500 additional shares (410,000 + 15,500) after shareholder approval and subject to a 9.99 % blocker.

Does the filing include any financial performance data for Aptevo?

No. The Schedule 13G solely covers ownership information and contains no earnings or revenue figures.